Gilead Sciences, Inc. (GILD) Bundle
Understanding Gilead Sciences, Inc. (GILD) Revenue Streams
Understanding Gilead Sciences, Inc.’s Revenue Streams
Gilead Sciences, Inc. reported total revenues of $7.545 billion for the third quarter of 2024, reflecting a 7% increase compared to $7.051 billion in the same period of 2023.
Breakdown of Primary Revenue Sources
The revenue streams are primarily derived from product sales across various therapeutic areas:
- HIV Products: $5.073 billion (9% increase from $4.667 billion in Q3 2023)
- Liver Disease Products: $733 million (4% increase from $706 million in Q3 2023)
- Oncology Products: $816 million (6% increase from $769 million in Q3 2023)
- Other Products: $201 million (7% decrease from $216 million in Q3 2023)
- Veklury (remdesivir): $692 million (9% increase from $636 million in Q3 2023)
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rates for the nine months ended September 30, 2024, are as follows:
| Revenue Source | 2024 (in millions) | 2023 (in millions) | Growth Rate (%) |
|---|---|---|---|
| HIV | $14,160 | $13,482 | 5% |
| Liver Disease | $2,302 | $2,093 | 10% |
| Oncology | $2,446 | $2,167 | 13% |
| Other | $705 | $658 | 7% |
| Veklury | $1,461 | $1,465 | 0% |
Contribution of Different Business Segments to Overall Revenue
The total product sales excluding Veklury for the third quarter of 2024 amounted to $6.823 billion, an increase of 7% year-over-year.
Analysis of Significant Changes in Revenue Streams
One significant change observed is the increase in HIV product sales, driven primarily by:
- Biktarvy: Sales increased to $3.472 billion from $3.085 billion, reflecting a 13% increase year-over-year.
- Descovy: Sales rose to $586 million from $511 million, marking a 15% increase year-over-year.
- Veklury: Sales grew to $692 million compared to $636 million in the previous year, indicating a 9% increase due to higher COVID-19 hospitalization rates.
A Deep Dive into Gilead Sciences, Inc. (GILD) Profitability
A Deep Dive into Gilead Sciences, Inc. Profitability
Gross Profit Margin: For the third quarter of 2024, the product gross margin was 79.1%, an increase from 77.6% in the same period in 2023. The non-GAAP product gross margin was 86.8%, compared to 85.9% year-over-year.
Operating Profit Margin: The operating margin for the third quarter of 2024 was 11.8%, significantly down from 37.2% in the third quarter of 2023. The non-GAAP operating margin was 43.2% compared to 45.7% in the previous year.
Net Profit Margin: The net income attributable to the company for the third quarter of 2024 was $1.253 billion, translating to a net profit margin of approximately 16.6% on total revenues of $7.545 billion. This is a decrease from $2.180 billion in the third quarter of 2023.
Trends in Profitability Over Time
Over the past year, profitability metrics have shown volatility. The gross margin increased, but operating and net margins have declined significantly due to higher costs related to in-process research and development (IPR&D) impairments. The latest figures indicate:
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Product Gross Margin | 79.1% | 77.6% | +1.5% |
| Operating Margin | 11.8% | 37.2% | -25.4% |
| Net Profit Margin | 16.6% | 31.0% | -14.4% |
Comparison of Profitability Ratios with Industry Averages
When compared to industry averages, Gilead's profitability metrics show mixed results. The industry average for gross profit margins in the biotech sector is typically around 75%, placing Gilead above this benchmark. However, the operating margin of 11.8% falls short of the industry average of approximately 20%.
Analysis of Operational Efficiency
Operational efficiency has been a focal point for Gilead. The company has seen a rise in selling, general and administrative (SG&A) expenses as a percentage of revenues, which stood at 19.0% in Q3 2024, compared to 18.6% in Q3 2023. Additionally, research and development expenses as a percentage of revenues have decreased to 18.5% from 20.7% over the same period, indicating better cost management in R&D.
The company reported a significant impairment charge of $1.75 billion related to IPR&D, which had a substantial impact on overall profitability. Despite these challenges, Gilead's management has indicated a focus on maintaining operational discipline moving forward.
Debt vs. Equity: How Gilead Sciences, Inc. (GILD) Finances Its Growth
Debt vs. Equity: How Gilead Sciences, Inc. Finances Its Growth
Overview of Debt Levels
As of September 30, 2024, Gilead Sciences reported a total debt of $19.9 billion, which includes both long-term and short-term debt. The long-term debt accounts for $18.3 billion, while the short-term debt stands at $1.6 billion.
Debt-to-Equity Ratio
The debt-to-equity ratio for Gilead Sciences as of September 30, 2024, is calculated at 1.08. This ratio indicates that for every dollar of equity, the company has $1.08 in debt. Industry standards typically range from 0.5 to 1.5, placing Gilead within a moderate risk zone compared to its peers.
Recent Debt Issuances and Credit Ratings
In the third quarter of 2024, Gilead issued $3.0 billion in senior unsecured notes to finance the acquisition of CymaBay Therapeutics, Inc. The company's credit rating stands at Baa1 from Moody's and BBB+ from S&P, indicating a stable outlook despite the recent debt increase.
Debt Refinancing Activity
Gilead successfully refinanced a portion of its existing debt in 2024, extending the maturity profile and reducing interest costs. The effective interest rate on its debt portfolio is currently 3.7%, down from 4.2% in the previous year.
Balancing Debt Financing and Equity Funding
In terms of capital structure, Gilead has utilized a combination of debt and equity funding to finance its growth initiatives. The company reported $18.39 billion in stockholders' equity as of September 30, 2024. This balance reflects the company's strategy of leveraging debt for growth while maintaining a robust equity base.
| Financial Metric | Value |
|---|---|
| Total Debt | $19.9 billion |
| Long-term Debt | $18.3 billion |
| Short-term Debt | $1.6 billion |
| Debt-to-Equity Ratio | 1.08 |
| Senior Unsecured Notes Issued | $3.0 billion |
| Credit Rating (Moody's) | Baa1 |
| Credit Rating (S&P) | BBB+ |
| Effective Interest Rate | 3.7% |
| Stockholders' Equity | $18.39 billion |
Assessing Gilead Sciences, Inc. (GILD) Liquidity
Assessing Gilead Sciences, Inc. Liquidity
Current Ratio: As of September 30, 2024, the current assets amounted to $14.0 billion while current liabilities were $7.7 billion, resulting in a current ratio of 1.82.
Quick Ratio: The quick assets (current assets minus inventories) totaled $10.6 billion, leading to a quick ratio of 1.38.
Analysis of Working Capital Trends
Working Capital: The working capital as of September 30, 2024, was $6.3 billion, indicating a healthy buffer for operational needs.
Trends: Working capital has increased from $5.4 billion as of December 31, 2023, reflecting improved liquidity management.
Cash Flow Statements Overview
Operating Cash Flow: For the third quarter of 2024, net cash provided by operating activities was $4.3 billion, up from $1.8 billion in the same quarter of 2023.
Investing Cash Flow: Cash used in investing activities for the third quarter 2024 was $710 million, compared to $229 million in 2023, primarily due to acquisitions.
Financing Cash Flow: Cash used in financing activities was $1.4 billion in Q3 2024, down from $1.5 billion in Q3 2023.
| Cash Flow Type | Q3 2024 (in millions) | Q3 2023 (in millions) |
|---|---|---|
| Operating Cash Flow | $4,309 | $1,756 |
| Investing Cash Flow | ($710) | ($229) |
| Financing Cash Flow | ($1,379) | ($1,518) |
Potential Liquidity Concerns or Strengths
Liquidity Strengths: The company maintains a strong cash position with $5.0 billion in cash and cash equivalents as of September 30, 2024.
Liquidity Concerns: The significant drop in cash from $8.4 billion at the end of 2023 to $5.0 billion is primarily attributed to a $3.9 billion acquisition, which could raise questions regarding future liquidity under changing market conditions.
Is Gilead Sciences, Inc. (GILD) Overvalued or Undervalued?
Valuation Analysis
To assess the valuation of Gilead Sciences, Inc. (GILD), we will analyze key financial ratios, stock price trends, dividend yield, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The P/E ratio is a crucial metric for evaluating whether a stock is overvalued or undervalued. As of November 2024, Gilead's P/E ratio stands at 12.4, based on earnings per share (EPS) of $1.00 for the third quarter of 2024.
Price-to-Book (P/B) Ratio
The P/B ratio provides insight into how the market values a company's equity relative to its book value. Gilead's P/B ratio is 2.0, with total stockholders' equity reported at $18.39 billion.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The EV/EBITDA ratio is another key valuation metric. Gilead's enterprise value is approximately $56.7 billion, with EBITDA for the trailing twelve months at $5.33 billion, resulting in an EV/EBITDA ratio of 10.6.
Stock Price Trends
Over the last 12 months, Gilead's stock price has experienced fluctuations. As of November 2024, the stock price is $12.40, up from $10.50 a year ago, indicating an increase of 18.1%.
Dividend Yield and Payout Ratios
Gilead has a dividend yield of 6.2%, with annual dividends declared at $2.31 per share. The payout ratio is 77%, indicating a substantial portion of earnings is returned to shareholders.
Analyst Consensus
According to recent analyst ratings, Gilead is generally rated as a Hold with a consensus target price of $13.50. This reflects a cautious outlook among analysts regarding the stock's future performance.
| Metric | Value |
|---|---|
| P/E Ratio | 12.4 |
| P/B Ratio | 2.0 |
| EV/EBITDA | 10.6 |
| Current Stock Price | $12.40 |
| 12-Month Stock Price Change | 18.1% |
| Dividend Yield | 6.2% |
| Annual Dividends | $2.31 |
| Payout Ratio | 77% |
| Analyst Consensus Rating | Hold |
| Consensus Target Price | $13.50 |
Key Risks Facing Gilead Sciences, Inc. (GILD)
Key Risks Facing Gilead Sciences, Inc.
Gilead Sciences, Inc. operates in a highly competitive pharmaceutical landscape, exposing it to various internal and external risks that can significantly impact its financial health.
Overview of Internal and External Risks
Key risk factors include:
- Industry Competition: Gilead faces intense competition from both established pharmaceutical companies and emerging biotech firms. The competitive landscape is characterized by rapid innovation and product development, particularly in HIV and oncology markets.
- Regulatory Changes: Changes in healthcare regulations and pricing pressures from government policies can adversely affect Gilead's market access and revenue potential.
- Market Conditions: Economic downturns and changes in healthcare spending can impact Gilead’s sales, particularly for its specialty products.
Operational Risks
Operational risks highlighted in recent earnings reports include:
- In-Process Research and Development (IPR&D) Impairments: In the third quarter of 2024, Gilead reported a pre-tax IPR&D impairment of $1.75 billion, primarily related to assets acquired from Immunomedics in 2020.
- Acquisition-Related Costs: Acquired IPR&D expenses reached $505 million in Q3 2024, driven by a significant charge related to the buy-out of royalties.
- Sales Fluctuations: Sales of key products such as Yescarta® decreased by 1% to $387 million in Q3 2024 due to increased competition.
Financial Risks
Financial risks include:
- Declining Earnings: The diluted earnings per share (EPS) was $1.00 in Q3 2024, a decrease from $1.73 in the same period in 2023.
- Effective Tax Rate Volatility: The effective tax rate was (31.1)% in Q3 2024 compared to 6.3% in Q3 2023, reflecting significant tax adjustments.
- Cash Reserves Decrease: Cash, cash equivalents, and marketable securities decreased to $5.0 billion as of September 30, 2024, down from $8.4 billion at the end of 2023.
Strategic Risks
Strategic risks mentioned in the latest earnings report include:
- Product Pipeline Reliance: Heavy reliance on the success of new product launches, such as lenacapavir for HIV prevention, which is still subject to regulatory approval.
- Market Access Challenges: The potential for limited access to markets due to regulatory hurdles can impede revenue growth.
Mitigation Strategies
Gilead has implemented several strategies to mitigate these risks:
- Operational Efficiency Improvements: Ongoing efforts to streamline operations and reduce costs are in place, aiming to maintain profitability despite rising operational expenses.
- Robust R&D Investment: Continued investment in research and development is essential to foster innovation and maintain a competitive edge in the market.
- Diverse Product Portfolio: Gilead is focusing on expanding its product offerings to reduce dependence on any single product line, thereby minimizing the impact of competitive pressures.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| IPR&D Impairment | Pre-tax impairment of $1.75 billion in Q3 2024 | Significant reduction in net income |
| Acquired IPR&D Expenses | Expenses of $505 million in Q3 2024 | Higher operational costs |
| Sales Declines | Yescarta sales decreased by 1% to $387 million | Potential revenue loss |
| Cash Reserves | Cash reserves decreased to $5.0 billion | Reduced liquidity for operations and investments |
| Effective Tax Rate | Effective tax rate at (31.1)% in Q3 2024 | Fluctuations in net income |
Future Growth Prospects for Gilead Sciences, Inc. (GILD)
Future Growth Prospects for Gilead Sciences, Inc.
Analysis of Key Growth Drivers
The company is focusing on several key growth drivers that are expected to enhance its market position:
- Product Innovations: The company is preparing for the potential launch of lenacapavir, a twice-yearly HIV prevention option, which demonstrated a 96% reduction in HIV infections in clinical trials.
- Market Expansions: The U.S. launch of Livdelzi for primary biliary cholangitis is a significant step towards expanding its product offerings in liver diseases.
- Acquisitions: The acquisition of CymaBay Therapeutics for approximately $3.9 billion is aimed at bolstering its treatment portfolio.
Future Revenue Growth Projections and Earnings Estimates
For the full year 2024, projected product sales are expected to range from $27.8 billion to $28.1 billion, with an increase in sales excluding Veklury from $26 billion to $26.3 billion. The company anticipates a diluted EPS of $0.05 to $0.25.
Strategic Initiatives or Partnerships
Strategic initiatives include:
- Collaborative Agreements: The company has signed royalty-free licensing agreements with six manufacturers for generic lenacapavir in resource-limited countries.
- Ongoing Collaborations: Payments related to ongoing collaborations have been identified as a key area of focus, particularly in the context of acquired in-process research and development expenses totaling $505 million in Q3 2024.
Competitive Advantages
The competitive advantages that position the company for growth include:
- Strong Product Portfolio: The HIV product portfolio, particularly Biktarvy, which saw a 13% increase in sales to $3.5 billion in Q3 2024.
- Robust Research and Development: R&D expenses as a percentage of revenues were 18.5% in Q3 2024, reflecting a commitment to innovation.
- High Product Gross Margin: The product gross margin was 79.1% in Q3 2024, indicating strong profitability.
Financial Overview
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Total Revenue | $7.5 billion | $7.0 billion | 7% |
| Product Sales | $7.5 billion | $6.99 billion | 7% |
| HIV Product Sales | $5.1 billion | $4.67 billion | 9% |
| Operating Cash Flow | $4.3 billion | $1.8 billion | 142% |
| Net Income | $1.25 billion | $2.18 billion | -43% |
| Diluted EPS | $1.00 | $1.73 | -42% |
Gilead Sciences, Inc. (GILD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Gilead Sciences, Inc. (GILD) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Gilead Sciences, Inc. (GILD)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Gilead Sciences, Inc. (GILD)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.